Optimizing the use of XXXX in renal transplantation.

@entity1 @entity205 @entity870
OBJECTIVE: To review the existing data on the use of @entity205 ( @entity870 ) in kidney transplantation, particularly with respect to therapeutic drug monitoring. DATA SOURCES: A literature search was conducted of applicable articles related to therapeutic drug monitoring of @entity205 in renal transplantation. Previous consensus guidelines were examined. Discussions on issues related to this topic convened in Toronto, ON, on June 15-16, 1994. DATA SYNTHESIS: The literature was analyzed to examine @entity1 factors and drug interactions affecting @entity870 concentrations, the effect of @entity870 concentrations on @entity1 outcome, current methods of analysis, pharmacodynamic monitoring, and new immunosuppressants. CONCLUSIONS: @entity870 has improved the success of kidney transplantation, reducing the incidence and severity of acute rejection and improving short-term @entity1 and graft survival. The rate of graft loss after the first year (primarily due to chronic rejection) has remained largely unchanged. Sandimmune Neoral offers promise due to its better bioavailability and limited dependence on bile flow for absorption. Long-term studies are underway to determine its effectiveness and safety. Indications for therapeutic drug monitoring for @entity870 are provided.
